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Low Levels of Circulating
Troponin as an Intermediate
Phenotype in the Pathway
to Heart Failure*
James A. de Lemos, MD,
Scott M. Grundy, MD, PHD
Dallas, Texas
The current indications for measurement of cardiac tro-
ponin T (cTnT) and cardiac troponin I (cTnI) primarily
focus on diagnosis and risk stratification in patients with
suspected myocardial infarction (MI). Recently, highly sen-
sitive assays for cTnT and cTnI have been developed that
can detect troponin concentrations 10-fold lower than is
possible with assays currently in use in the United States.
See page 484
These assays improve sensitivity for the detection of MI,
particularly early after symptom onset, at a cost of decreased
specificity (1,2). Importantly, the ability to detect very low
circulating troponin levels with these assays has opened the
door for many additional potential applications for troponin
measurement, both for clinical and for research purposes.
With the highly sensitive cTnT (hs-cTnT) and assay, for
example, it is possible to detect circulating cTnT in virtually
all patients with chronic coronary artery disease or conges-
tive heart failure (3,4); moreover, 25% to 67% of adults from
the general population have detectable troponin levels with
this assay (5–7). The augmented sensitivity of these assays
has facilitated exploration of the cardiovascular “phenotype”
associated with low circulating levels of troponin in asymp-
tomatic individuals, including associations with both sub-
clinical cardiovascular disease as well as future clinical
events.
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to disclose.Recent studies have demonstrated that among individuals
in the general population and among stable patients with
chronic cardiovascular disease, measurable circulating tro-
ponin levels reflect chronic sources of myocardial injury,
rather than acute processes, and better predict long-term
heart failure risk than ischemic risk (3,5–7). In the Dallas
Heart study, for example, robust, independent associations
were observed between higher cTnT and magnetic reso-
nance imaging-defined measures of abnormal cardiac struc-
ture and function, such as left ventricular (LV) hypertrophy
and LV dysfunction, but no independent association was
seen with coronary artery calcium, a measure of atheroscle-
rosis (5). Furthermore, in 2 large population-based studies,
the ARIC (Atherosclerosis Risk in Communities) study and
the Cardiovascular Health Study, associations with cTnT
were much stronger for incident heart failure than for MI
(6,7). Finally, even among patients with a prior MI,
higher levels of cTnT predict heart failure events but not
recurrent MI (3).
In aggregate, these findings suggest that low circulating
levels of troponin, detectable now with highly sensitive
assays, may indicate subclinical chronic myocardial injury
and thereby identify heightened risk for pathological cardiac
remodeling and the development of heart failure. In this
issue of the Journal, Rubin et al. (8) from the ARIC study
capitalize on these observations, utilizing cTnT not as an
exposure variable, but rather as an intermediate phenotype
of subclinical cardiac injury. The focus of the study is on
correlations between chronic hyperglycemia, as measured by
the glycated hemoglobin (HbA1c) concentration, and levels
of cTnT. HbA1c was measured in almost 10,000 persons
free from coronary heart disease (CHD) or heart failure
between 1990 and 1992, with cTnT measured from frozen
plasma samples collected approximately 6 years later.
“Dose-dependent” associations were seen between HbA1c
and cTnT, both among persons who had diabetes and those
who did not. After adjustment for traditional cardiovascular
risk factors, chronic kidney disease, and prevalent LV hyper-
trophy, the associations remained significant but were attenu-
ated in magnitude, suggesting that some of the association of
chronic hyperglycemia with cardiac injury is likely mediated
through shared risk factors. In contrast to HbA1c, fasting
glucose did not associate with cTnT after multivariable adjust-
ment.
The major limitation of this study is the 6-year interval
between measurement of HbA1c and cTnT. The investi-
gators attempted to account for interval events between the
2 study visits, performing sensitivity analyses excluding
participants who had or developed chronic kidney disease,
stroke, or atrial fibrillation before the cTnT measurement,
which did not alter the findings. These analyses are impor-
tant because it is clear that variability in cTnT levels in the
population is influenced not only by structural heart disease,
but also by renal function and other comorbid cardiac and
noncardiac conditions (5,9). However, these analyses do not
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delay between measurements. For example, it possible that
progression to more mild forms of chronic kidney disease
could explain, in part, the associations of HbA1c with
troponin elevation. In addition, progression of hyperglyce-
mia between study visits may have led to initiation of
glucose-lowering therapy. It is plausible that hypoglycemic
medications, most notably sulfonylurea agents (10), could
cause or contribute to cardiac injury. It would be useful to
investigate further whether specific glucose-lowering thera-
pies cause an increase in troponin among persons without
known cardiovascular disease.
Chronic hyperglycemia is commonly believed to contribute
to premature cardiovascular disease morbidity and mortality by
promoting atherosclerosis development and progression.
However, it has not been proven that hyperglycemia acceler-
ates atherogenesis. The current findings (8) provide evidence,
lbeit circumstantial, to support a role for nonatherosclerotic
echanisms by which chronic hyperglycemia may lead to
yocardial injury, and eventually, heart failure. Because
rior epidemiologic evidence indicates that cTnT reflects
yocardial rather than coronary artery pathophysiology in
symptomatic persons, and because the present analyses
xcluded participants with CHD and accounted for poten-
ial confounding from kidney disease and other potential
auses of elevated cTnT, these conclusions appear to be
easonable.
Although diabetes has long been implicated as a predis-
osing factor for heart failure (11), with greater risk at
igher HgA1c concentrations (12), the concept of a specific
diabetic cardiomyopathy” has been more controversial.
ther than through promotion of atherosclerosis leading to
linically evident and silent myocardial infarction, the spe-
ific mechanisms by which chronic hyperglycemia contrib-
tes to myocardial injury remain speculative. Alterations in
etabolic substrate for the heart (13), coronary microvas-
ular dysfunction (14), increased oxidant stress (15), en-
anced fibrosis (16), and the downstream effects of ad-
anced glycation end products (17) are commonly cited as
otential culprits for myocardial dysfunction among patients
ith diabetes, but less is known regarding the influence of
ore mild forms of chronic hyperglycemia. The present
tudy (8), which demonstrates that associations of HbA1c
ith cTnT extend to persons with HbA1c levels below the
iabetes diagnostic threshold of 6.5%, suggests that non-
therosclerotic cardiac injury related to hyperglycemia may
egin earlier in the disease process, before the onset of
linically evident diabetes.
These intriguing findings should prompt further explo-
ation of the role of chronic hyperglycemia in early pathways
eading to heart failure development in both animal and
uman models. Longitudinal studies, incorporating serial
ardiac imaging studies, are needed to evaluate patterns of
ardiac remodeling among patients with chronic hypergly-
emia and low levels of circulating troponins. Intervention
tudies, evaluating the influence of glucose control strategiesn troponin levels, as well as cardiac structure and function
nd heart failure outcomes, will provide further insight.
The paper by Rubin et al. (8) is the first of what will likely
e many papers considering circulating troponins as inter-
ediate phenotypes or surrogate endpoints for heart failure
nd mortality risk among asymptomatic persons. The un-
erlying implication of such analyses is that if one could
odify the exposure variable, for example, by improving
hronic glucose control, it may be possible to prevent
ubclinical myocardial damage, and thus prevent the devel-
pment of heart failure. However, while overwhelming
vidence supports preventing or minimizing troponin ele-
ation in the setting of suspected ACS, such that troponins
re now a cornerstone for MI diagnosis (18), limited data
xist suggesting that modifying troponin release among
symptomatic ambulatory persons is associated with benefit.
reliminary findings among patients with chronic heart
ailure (4) and older adults from the general population (6),
uggest that increases in cTnT over a 2- to 3-year period are
ssociated with a higher risk for death and heart failure,
hereas a reduction in levels are associated with lower risk.
nterpretation of these findings is not straightforward,
owever, as troponin variation over time may have been
nfluenced by acute and chronic factors other than progres-
ion of subclinical myocardial pathology, which were not
ully considered in these studies.
Before troponin levels can be considered as a validated
ntermediate phenotype in the pathway to heart failure,
dditional studies are needed linking changes in troponins
ith cardiovascular and noncardiovascular outcomes, and
nvestigating the role of specific therapies on troponin
elease and subsequent events. These studies should be a
igh priority, as they will have the potential to facilitate
arlier interventions to prevent heart failure.
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